The efficacy and tolerability of tolterodine ER Vs .
A recent meta- analysis evaluating tolterodine in comparison with other antimuscarinic drugs demonstrated that tolterodine ER was significantly more effective than placebo in reducing micturition/24 h , urinary leakage episodes/24 h , urgency episodes/24 h , and urgency incontinence episodes/24 h. With regard to adverse events , tolterodine ER was associated with a good adverse event profile result ing in the third most favorable antimuscarinic .
Conclusion Tolterodine ER result ed effective in reducing frequency urgency and nocturia and urinary leakage in male patients with OAB/storage LUTS .
Dry mouth and constipation are the most frequently reported adverse events
Background Overactive bladder (OAB)/ storage lower urinary tract symptoms ( LUTS ) have a high prevalence affecting up to 90 % of men over 80 years .
The role of sufficient therapies appears crucial .
In the present review , we analyzed the mechanism of action of tolterodine extended-release ( ER ) with the aim to clarify its efficacy and safety profile , as compared to other active treatments of OAB/storage LUTS .
Antimuscarinic drugs are the mainstay of pharmacological therapy for OAB / storage LUTS ; several studies have demonstrated that tolterodine ER is an effective and well tolerated formulation of this class of treatment .
Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data.
OBJECTIVES To summarize the efficacy and safety of tolterodine from the pooled data of four multicenter , r and omized , double-blind , placebo-controlled , dose-ranging , parallel-group Phase II studies in patients with urodynamically proved overactive bladder ( detrusor instability or detrusor hyperreflexia ) and to analyze the concentration-effect relation . METHODS After a 1-week run-in period to establish baseline values , 319 patients were r and omized to receive  placebo or tolterodine  0.5 , 1 , 2 , or 4 mg twice daily . Micturition diary and urodynamic variables and subjective urinary symptoms were assessed after 2 weeks of treatment . Patients were classified as " extensive " or " poor " metabolizers of tolterodine on the basis of serum levels of tolterodine . RESULTS A per- protocol analysis of efficacy in 262 patients showed dose-related improvements in micturition diary and urodynamic variables . A dosage of 4 mg twice daily was , however , associated with an increase in residual urinary volume . The incidence of adverse events ( mainly mild or moderate antimuscarinic effects ) was comparable between placebo and tolterodine dosages of 2 mg twice daily . No serious drug-related adverse events were observed , and tolterodine had no clinical ly significant impact on electrocardiographic or laboratory findings . Changes in urodynamic variables were found to be related to the sum of unbound serum concentrations of  tolterodine  and its major active 5-hydroxymethyl metabolite . In poor and extensive metabolizers of tolterodine , exposure to the sum of these active moieties was similar , and the efficacy and safety profiles were comparable . CONCLUSIONS The results of this pooled data analysis indicate that tolterodine offers an effective treatment for patients with urinary symptoms attributable to overactive bladder . The optimal dosage is 1 to 2 mg twice daily , irrespective of metabolic phenotype
The efficacy and tolerability of tolterodine ER Vs .
A recent meta- analysis evaluating tolterodine in comparison with other antimuscarinic drugs demonstrated that tolterodine ER was significantly more effective than placebo in reducing micturition/24 h , urinary leakage episodes/24 h , urgency episodes/24 h , and urgency incontinence episodes/24 h. With regard to adverse events , tolterodine ER was associated with a good adverse event profile result ing in the third most favorable antimuscarinic .
Conclusion Tolterodine ER result ed effective in reducing frequency urgency and nocturia and urinary leakage in male patients with OAB/storage LUTS .
Dry mouth and constipation are the most frequently reported adverse events
Background Overactive bladder (OAB)/ storage lower urinary tract symptoms ( LUTS ) have a high prevalence affecting up to 90 % of men over 80 years .
The role of sufficient therapies appears crucial .
In the present review , we analyzed the mechanism of action of tolterodine extended-release ( ER ) with the aim to clarify its efficacy and safety profile , as compared to other active treatments of OAB/storage LUTS .
Antimuscarinic drugs are the mainstay of pharmacological therapy for OAB / storage LUTS ; several studies have demonstrated that tolterodine ER is an effective and well tolerated formulation of this class of treatment .